Contributions
Abstract: EP1650
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Background: Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting MS. The Teri-PRO study (NCT01895335) previously reported high levels of treatment satisfaction with teriflunomide in routine clinical practice. The global nature of Teri-PRO allows for an assessment of the influence of different treatment practices on outcomes among participating countries.
Objective: To report treatment satisfaction with teriflunomide in the European cohort of the Teri-PRO study.
Methods: Patients in Europe received teriflunomide 14 mg, according to local labelling. The primary outcome was Global Satisfaction with treatment at Week (W) 48, measured using the Treatment Satisfaction Questionnaire for Medication (TSQM, version 1.4). TSQM scores were measured at baseline (patients switching from a prior disease-modifying therapy [DMT] within the previous 6 months), and at W4 and W48/end of treatment (all patients). In this post hoc analysis, patients in Europe were stratified into 4 regions: Nordics (Norway, Finland, and Sweden), Southern Europe (SE; Greece, Italy, and Spain), Central Europe (CE; France, Belgium, Austria, and Germany), and the UK.
Results: Mean (SD) age (years) was 43.8 (9.3) in the Nordics (n=63), 41.7 (9.3) in SE (n=121), 42.5 (10.6) in CE (n=205), and 45.3 (9.1) in the UK (n=44); baseline EDSS score was 1.8 (1.4), 2.3 (1.5), 2.1 (1.3), and 3.2 (1.9), respectively. TSQM Global Satisfaction remained high over the study period in all regions (mean [95% CI]; Nordics: W4 73.1 [68.0,78.1], W48 71.9 [65.6,78.2]; SE: W4, 68.7 [65.6,71.7], W48 64.2 [59.8,68.5]; CE: W4 72.2 [69.2,75.3], W48 66.8 [63.1,70.6]; UK: W4 80.4 [74.5,86.4], W48 76.2 [68.1,84.2]). In patients switching from another DMT, Global Satisfaction significantly improved from baseline to W4 (Nordics: baseline 57.3 [50.5,64.2], W4 75.7 [70.1,81.2], P=0.0192; SE: baseline 52.9 [47.7,58.0], W4 72.0 [68.3,75.6], P< 0.0001; CE: baseline 56.7 [51.9,61.5], W4 75.4 [71.7,79.0],
P< 0.0001; UK: baseline 43.5 [31.0,55.9], W4 80.0 [71.0,89.1], P=0.0003) and remained high to W48 (Nordics: W48 75.3 [68.2,82.3], P=0.0840 vs baseline; SE: W48 64.2 [58.9,69.4], P=0.0335; CE: W48 69.9 [65.2,74.6], P< 0.0001; UK: W48 72.2 [59.1,85.3], P=0.0209).
Conclusions: High levels of treatment satisfaction were observed in Europe regardless of region, including significant improvements in patients switching from another DMT. These results are consistent with the full study population.
Disclosure: Study supported by Sanofi Genzyme.
PV: Honoraria, consulting fees (Almirall, Bayer, Biogen Idec, Genzyme/Sanofi, GSK, Merck Serono, Novartis, Teva); research support (Bayer, Biogen Idec, Genzyme/Sanofi, Merck Serono).
JML: Consulting fees (Almirall, Biogen Idec, Merck Serono, Novartis, Sanofi, Teva).
EM: Consulting fees (Teva), travel grants (Novartis).
VvP: Travel grant (Biogen, Bayer Schering, Genzyme, Merck, Roche, Sanofi Genzyme and Teva). Author´s institution has received honoraria for consultancy and lectures (Biogen, Bayer Schering, Merck, Novartis Pharma, Roche, Sanofi Genzyme, and Teva) and research grants (Bayer Schering, Novartis Pharma, Roche, and Sanofi Genzyme).
HK: Consulting fees and travel grants (Biogen, Genzyme, Merck, Novartis, Teva).
GC: Compensation in past year for consulting services and/or speaking activities (Almirall, Biogen, Celgene, Excemed, Forward Pharma, Genzyme, Merck, Novartis, Receptos, Roche, Sanofi, Teva); fees from non-CME services (Almirall, Bayer, Biogen, Excemed, Genzyme, Merck Serono, Novartis, Receptos, Sanofi, SSIF, Teva).
RJ: Consulting fees (Almirall, Biogen, Genzyme/Sanofi, Merck, Novartis).
WR: Nothing to disclose.
NF: Honoraria, consulting fees (Allergan, Bayer, Merck Serono, Novartis, Roche, Sanofi/Genzyme, Teva), research support (Actelion, Amgen, Biogen, Celgene, Merck Serono, Novartis, Receptos, Roche, Sanofi/Genzyme, Teva).
PR and EP: Employees of Sanofi Genzyme.
RG: Consulting fees (Bayer Schering, Biogen, Elan, Genzyme, Roche, Teva); grant/research support (Bayer Schering, Biogen, Genzyme, Teva).
Abstract: EP1650
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Background: Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing-remitting MS. The Teri-PRO study (NCT01895335) previously reported high levels of treatment satisfaction with teriflunomide in routine clinical practice. The global nature of Teri-PRO allows for an assessment of the influence of different treatment practices on outcomes among participating countries.
Objective: To report treatment satisfaction with teriflunomide in the European cohort of the Teri-PRO study.
Methods: Patients in Europe received teriflunomide 14 mg, according to local labelling. The primary outcome was Global Satisfaction with treatment at Week (W) 48, measured using the Treatment Satisfaction Questionnaire for Medication (TSQM, version 1.4). TSQM scores were measured at baseline (patients switching from a prior disease-modifying therapy [DMT] within the previous 6 months), and at W4 and W48/end of treatment (all patients). In this post hoc analysis, patients in Europe were stratified into 4 regions: Nordics (Norway, Finland, and Sweden), Southern Europe (SE; Greece, Italy, and Spain), Central Europe (CE; France, Belgium, Austria, and Germany), and the UK.
Results: Mean (SD) age (years) was 43.8 (9.3) in the Nordics (n=63), 41.7 (9.3) in SE (n=121), 42.5 (10.6) in CE (n=205), and 45.3 (9.1) in the UK (n=44); baseline EDSS score was 1.8 (1.4), 2.3 (1.5), 2.1 (1.3), and 3.2 (1.9), respectively. TSQM Global Satisfaction remained high over the study period in all regions (mean [95% CI]; Nordics: W4 73.1 [68.0,78.1], W48 71.9 [65.6,78.2]; SE: W4, 68.7 [65.6,71.7], W48 64.2 [59.8,68.5]; CE: W4 72.2 [69.2,75.3], W48 66.8 [63.1,70.6]; UK: W4 80.4 [74.5,86.4], W48 76.2 [68.1,84.2]). In patients switching from another DMT, Global Satisfaction significantly improved from baseline to W4 (Nordics: baseline 57.3 [50.5,64.2], W4 75.7 [70.1,81.2], P=0.0192; SE: baseline 52.9 [47.7,58.0], W4 72.0 [68.3,75.6], P< 0.0001; CE: baseline 56.7 [51.9,61.5], W4 75.4 [71.7,79.0],
P< 0.0001; UK: baseline 43.5 [31.0,55.9], W4 80.0 [71.0,89.1], P=0.0003) and remained high to W48 (Nordics: W48 75.3 [68.2,82.3], P=0.0840 vs baseline; SE: W48 64.2 [58.9,69.4], P=0.0335; CE: W48 69.9 [65.2,74.6], P< 0.0001; UK: W48 72.2 [59.1,85.3], P=0.0209).
Conclusions: High levels of treatment satisfaction were observed in Europe regardless of region, including significant improvements in patients switching from another DMT. These results are consistent with the full study population.
Disclosure: Study supported by Sanofi Genzyme.
PV: Honoraria, consulting fees (Almirall, Bayer, Biogen Idec, Genzyme/Sanofi, GSK, Merck Serono, Novartis, Teva); research support (Bayer, Biogen Idec, Genzyme/Sanofi, Merck Serono).
JML: Consulting fees (Almirall, Biogen Idec, Merck Serono, Novartis, Sanofi, Teva).
EM: Consulting fees (Teva), travel grants (Novartis).
VvP: Travel grant (Biogen, Bayer Schering, Genzyme, Merck, Roche, Sanofi Genzyme and Teva). Author´s institution has received honoraria for consultancy and lectures (Biogen, Bayer Schering, Merck, Novartis Pharma, Roche, Sanofi Genzyme, and Teva) and research grants (Bayer Schering, Novartis Pharma, Roche, and Sanofi Genzyme).
HK: Consulting fees and travel grants (Biogen, Genzyme, Merck, Novartis, Teva).
GC: Compensation in past year for consulting services and/or speaking activities (Almirall, Biogen, Celgene, Excemed, Forward Pharma, Genzyme, Merck, Novartis, Receptos, Roche, Sanofi, Teva); fees from non-CME services (Almirall, Bayer, Biogen, Excemed, Genzyme, Merck Serono, Novartis, Receptos, Sanofi, SSIF, Teva).
RJ: Consulting fees (Almirall, Biogen, Genzyme/Sanofi, Merck, Novartis).
WR: Nothing to disclose.
NF: Honoraria, consulting fees (Allergan, Bayer, Merck Serono, Novartis, Roche, Sanofi/Genzyme, Teva), research support (Actelion, Amgen, Biogen, Celgene, Merck Serono, Novartis, Receptos, Roche, Sanofi/Genzyme, Teva).
PR and EP: Employees of Sanofi Genzyme.
RG: Consulting fees (Bayer Schering, Biogen, Elan, Genzyme, Roche, Teva); grant/research support (Bayer Schering, Biogen, Genzyme, Teva).